Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea
| Autor: | Dominique Milea, Hong Jin Jeon, Rangrhee Jung, M. Brignone, Sang-Eun Choi, Seong Jin Cho, R. Campbell, Clément François |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Pediatrics
medicine.medical_specialty Time Factors Cost effectiveness Cost-Benefit Analysis Venlafaxine Hydrochloride Venlafaxine Sulfides Piperazines 03 medical and health sciences 0302 clinical medicine Recurrence Republic of Korea Humans Medicine Pharmacology (medical) 030212 general & internal medicine Psychiatry Depression (differential diagnoses) Vortioxetine Depressive Disorder Major business.industry Health Policy Decision Trees General Medicine medicine.disease Antidepressive Agents Markov Chains Quality-adjusted life year Treatment Outcome Delayed-Action Preparations Antidepressant Major depressive disorder Quality-Adjusted Life Years business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Expert Review of Pharmacoeconomics & Outcomes Research. 16:629-638 |
| ISSN: | 1744-8379 1473-7167 |
| DOI: | 10.1586/14737167.2016.1128830 |
| Popis: | To assess the cost-effectiveness of vortioxetine versus venlafaxine XR (extended-release) in major depressive disorder (MDD) patients in South Korea.A 1-year cost-effectiveness analysis from a limited societal perspective was performed using a combined model consisting of a decision-tree and a Markov model. Patients entered the model when initiating or switching antidepressant treatment following inadequate response to previous treatment. Remission, relapse and recovery were the main health states.Vortioxetine dominated venlafaxine XR, with quality-adjusted life year (QALY) gains of 0.0131 and cost savings of KRW 623,229/year [US$530/year] from a limited societal perspective. Safety contributed more than efficacy to the incremental QALY gains. More patients were in recovery after initial treatment and after 1 year with vortioxetine (31%, 40%) compared to venlafaxine XR (23%, 36%). Vortioxetine remained dominant in 98% of probabilistic simulations.Vortioxetine dominated venlafaxine XR in South Korea and is a relevant treatment option for MDD patients initiating or switching therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|